We are live on
!
Find out more
CA
Corriente Advisors Portfolio holdings
AUM
$9.53M
1-Year Est. Return
805.26%
This Fund
S&P 500
This Quarter
Est. Return
+36.1%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$197M
AUM Growth
+$42.9M
(+28%)
Cap. Flow
+$36.8M
Cap. Flow
% of AUM
18.69%
Top 10 Holdings %
Top 10 Hldgs %
91.19%
Holding
25
New
9
Increased
7
Reduced
–
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$19.1M |
| 2 |
Cue Biopharma
CUE
|
+$14.9M |
| 3 |
TFFP
TFF Pharmaceuticals, Inc. Common Stock
TFFP
|
+$12M |
| 4 |
Village Farms International
VFF
|
+$5.18M |
| 5 |
Cardiff Oncology
CRDF
|
+$4.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sonos
SONO
|
+$23M |
| 2 |
uniQure
QURE
|
+$8.11M |
| 3 |
Ocular Therapeutix
OCUL
|
+$6M |
| 4 |
Celldex Therapeutics
CLDX
|
+$5.98M |
| 5 |
Tesla
TSLA
|
+$2.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.92% |
| 2 | Technology | 27.01% |
| 3 | Consumer Staples | 5.14% |
| 4 | Industrials | 2.44% |
| 5 | Communication Services | 1.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAXR
1
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $49.2M | 24.94% |
1,972,061
+72,061
| +4% | +$1.6M |
|
|
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $29.2M | 14.82% |
300,000
+152,500
| +103% | +$19.1M |
|
|
3
Cue Biopharma
CUE
$131M
| $21.6M | 10.97% |
47,915
+25,915
| +118% | +$14.9M |
|
|
APTO
4
DELISTED
Aptose Biosciences, Inc.
APTO
| $20.6M | 10.44% |
7,622
+1,464
| +24% | +$3.65M |
|
|
TFFP
5
DELISTED
TFF Pharmaceuticals, Inc. Common Stock
TFFP
| $19.6M | 9.92% |
+42,353
| New | +$12M |
|
|
6
Cardiff Oncology
CRDF
$60.2M
| $12.9M | 6.55% |
910,000
+736,639
| +425% | +$4.86M |
|
7
Replimune Group
REPL
$859M
| $11.8M | 5.98% |
512,500
+27,500
| +6% | +$627K |
|
8
Beyond Meat
BYND
$305M
| $5.81M | 2.95% |
+35,000
| New | +$4.74M |
|
9
Virgin Galactic
SPCE
$329M
| $4.81M | 2.44% |
+12,500
| New | +$4.74M |
|
|
10
Village Farms International
VFF
$240M
| $4.32M | 2.19% |
+943,396
| New | +$5.18M |
|
11
Datadog
DDOG
$92.1B
| $4.09M | 2.07% |
+40,000
| New | +$3.48M |
|
|
SIOX
12
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $4.04M | 2.05% |
+875,000
| New | +$2.89M |
|
13
Roku
ROKU
$21.4B
| $3.78M | 1.91% |
+20,000
| New | +$3.16M |
|
14
DiaMedica Therapeutics
DMAC
$393M
| $3.1M | 1.57% |
730,000
+528,752
| +263% | +$2.8M |
|
|
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
| $122K | 0.06% |
+49,085
| New | +$145K |
|
16
Arrowhead Research
ARWR
$10.5B
| – | – |
-40,000
| Closed | -$1.73M |
|
|
17
Celldex Therapeutics
CLDX
$2.77B
| – | – |
-460,000
| Closed | -$5.98M |
|
|
18
Ocular Therapeutix
OCUL
$1.96B
| – | – |
-720,000
| Closed | -$6M |
|
19
Pan American Silver
PAAS
$17.6B
| – | – |
-30,000
| Closed | -$912K |
|
|
20
uniQure
QURE
$2.77B
| – | – |
-180,000
| Closed | -$8.11M |
|
|
RWT
21
Redwood Trust
RWT
$641M
| – | – |
-75,000
| Closed | -$525K |
|
|
22
Sonos
SONO
$1.8B
| – | – |
-1,570,000
| Closed | -$23M |
|
|
23
Tesla
TSLA
$1.43T
| – | – |
-30,000
| Closed | -$2.16M |
|
|
PVLA
24
Palvella Therapeutics
PVLA
$2.26B
| – | – |
-3,375
| Closed | -$837K |
|
Similar funds
SCM
FWM
TOPU
TGI
GIP
LCMP
SCM
TA
Corriente Advisors's Q3 2020 Portfolio in Review
As of Q3 2020, Corriente Advisors held 25 positions worth $197M, up 28% from $154M the previous quarter. Its ten largest holdings account for 91% of the portfolio.
Corriente Advisors deployed $36.8M of net new capital in Q3 2020, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was TFF Pharmaceuticals, Inc. Common Stock: 42,353 shares worth $19.6M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Consumer Staples.
On the sell side, the most notable exit was Sonos, an estimated $23M sold.
- Corriente Advisors's largest Q3 2020 buy was TFF Pharmaceuticals, Inc. Common Stock: 42,353 shares worth $19.6M.
- Corriente Advisors added most to Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020, an estimated $19.1M increase.
- Corriente Advisors fully exited Sonos in Q3 2020, selling an estimated $23M.
- Corriente Advisors's ten largest holdings make up 91% of its $197M portfolio in Q3 2020.
- Corriente Advisors opened 9 new positions and closed 9 in Q3 2020.
- Corriente Advisors's portfolio value rose 28% quarter-over-quarter to $197M.
Based on Corriente Advisors's 13F filing for Q3 2020, filed 3 Nov 2020.